Does the media prefer PLSE or BAX?

In the previous week, Pulse Biosciences had 2 more articles in the media than Baxter International. MarketBeat recorded 11 mentions for Pulse Biosciences and 9 mentions for Baxter International. Baxter International's average media sentiment score of 1.19 beat Pulse Biosciences' score of 0.77 indicating that Baxter International is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Baxter International 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, PLSE or PEN?

Penumbra has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 9,810.02 -$72.78M -$1.18 N/A Penumbra $1.40B 8.95 $177.69M $4.07 78.34

Does the media prefer PLSE or PEN?

In the previous week, Pulse Biosciences had 6 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Pulse Biosciences and 5 mentions for Penumbra. Penumbra's average media sentiment score of 0.92 beat Pulse Biosciences' score of 0.77 indicating that Penumbra is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, PLSE or SNN?

Smith & Nephew SNATS has higher revenue and earnings than Pulse Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pulse Biosciences $350K 9,810.02 -$72.78M -$1.18 N/A Smith & Nephew SNATS $6.16B 1.89 $625M N/A N/A

Does the media refer more to PLSE or SNN?

In the previous week, Pulse Biosciences had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Pulse Biosciences and 7 mentions for Smith & Nephew SNATS. Pulse Biosciences' average media sentiment score of 0.77 beat Smith & Nephew SNATS's score of 0.55 indicating that Pulse Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pulse Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer GMED or PLSE?

In the previous week, Pulse Biosciences had 3 more articles in the media than Globus Medical. MarketBeat recorded 11 mentions for Pulse Biosciences and 8 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat Pulse Biosciences' score of 0.77 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GKOS or PLSE more profitable?

Glaukos has a net margin of -30.68% compared to Pulse Biosciences' net margin of -6,755.78%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Glaukos -30.68% -6.37% -4.78% Pulse Biosciences -6,755.78% -94.42% -79.96%

Does the media favor GKOS or PLSE?

In the previous week, Pulse Biosciences had 6 more articles in the media than Glaukos. MarketBeat recorded 11 mentions for Pulse Biosciences and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.14 beat Pulse Biosciences' score of 0.77 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pulse Biosciences 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pulse Biosciences (PLSE) Competitors

$49.61 -5.59 (-10.13%)

Closing price 09/16/2026 04:00 PM Eastern

Extended Trading

$49.68 +0.07 (+0.15%)

As of 07:00 AM Eastern

Compare

PLSE vs. BAX, PEN, SNN, GMED, and GKOS

Should you buy Pulse Biosciences stock or one of its competitors? Pulse Biosciences's main competitors and comparable companies include Baxter International (BAX), Penumbra (PEN), Smith & Nephew SNATS (SNN), Globus Medical (GMED), and Glaukos (GKOS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Pulse Biosciences compare to Baxter International?

Pulse Biosciences (NASDAQ:PLSE) and Baxter International (NYSE:BAX) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

Pulse Biosciences has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Baxter International has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

Baxter International has a net margin of -9.27% compared to Pulse Biosciences' net margin of -6,755.78%. Baxter International's return on equity of 16.57% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Baxter International	-9.27%	16.57%	5.24%

In the previous week, Pulse Biosciences had 2 more articles in the media than Baxter International. MarketBeat recorded 11 mentions for Pulse Biosciences and 9 mentions for Baxter International. Baxter International's average media sentiment score of 1.19 beat Pulse Biosciences' score of 0.77 indicating that Baxter International is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Baxter International	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pulse Biosciences has higher earnings, but lower revenue than Baxter International. Pulse Biosciences is trading at a lower price-to-earnings ratio than Baxter International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,810.02	-$72.78M	-$1.18	N/A
Baxter International	$11.24B	1.08	-$957M	-$2.07	N/A

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 90.2% of Baxter International shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by insiders. Comparatively, 0.2% of Baxter International shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Pulse Biosciences presently has a consensus price target of $45.25, indicating a potential downside of 8.79%. Baxter International has a consensus price target of $22.45, indicating a potential downside of 4.49%. Given Baxter International's higher possible upside, analysts plainly believe Baxter International is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Baxter International	2 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Pulse Biosciences beats Baxter International on 9 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Penumbra?

Pulse Biosciences (NASDAQ:PLSE) and Penumbra (NYSE:PEN) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Pulse Biosciences currently has a consensus target price of $45.25, suggesting a potential downside of 8.79%. Penumbra has a consensus target price of $367.07, suggesting a potential upside of 15.13%. Given Penumbra's higher possible upside, analysts clearly believe Penumbra is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Penumbra	0 Sell rating(s)	14 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.18

Pulse Biosciences has a beta of 1.63, indicating that its share price is 63% more volatile than the broader market. Comparatively, Penumbra has a beta of 0.7, indicating that its share price is 30% less volatile than the broader market.

In the previous week, Pulse Biosciences had 6 more articles in the media than Penumbra. MarketBeat recorded 11 mentions for Pulse Biosciences and 5 mentions for Penumbra. Penumbra's average media sentiment score of 0.92 beat Pulse Biosciences' score of 0.77 indicating that Penumbra is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Penumbra	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Penumbra has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,810.02	-$72.78M	-$1.18	N/A
Penumbra	$1.40B	8.95	$177.69M	$4.07	78.34

77.0% of Pulse Biosciences shares are owned by institutional investors. Comparatively, 88.9% of Penumbra shares are owned by institutional investors. 74.0% of Pulse Biosciences shares are owned by company insiders. Comparatively, 2.9% of Penumbra shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Penumbra has a net margin of 10.67% compared to Pulse Biosciences' net margin of -6,755.78%. Penumbra's return on equity of 10.50% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Penumbra	10.67%	10.50%	8.17%

Summary

Penumbra beats Pulse Biosciences on 10 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Smith & Nephew SNATS?

Pulse Biosciences (NASDAQ:PLSE) and Smith & Nephew SNATS (NYSE:SNN) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Smith & Nephew SNATS has a net margin of 0.00% compared to Pulse Biosciences' net margin of -6,755.78%. Smith & Nephew SNATS's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%
Smith & Nephew SNATS	N/A	N/A	N/A

77.0% of Pulse Biosciences shares are held by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Pulse Biosciences had 4 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 11 mentions for Pulse Biosciences and 7 mentions for Smith & Nephew SNATS. Pulse Biosciences' average media sentiment score of 0.77 beat Smith & Nephew SNATS's score of 0.55 indicating that Pulse Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pulse Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Smith & Nephew SNATS	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Smith & Nephew SNATS has higher revenue and earnings than Pulse Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pulse Biosciences	$350K	9,810.02	-$72.78M	-$1.18	N/A
Smith & Nephew SNATS	$6.16B	1.89	$625M	N/A	N/A

Pulse Biosciences currently has a consensus price target of $45.25, suggesting a potential downside of 8.79%. Smith & Nephew SNATS has a consensus price target of $31.91, suggesting a potential upside of 14.72%. Given Smith & Nephew SNATS's higher possible upside, analysts clearly believe Smith & Nephew SNATS is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Smith & Nephew SNATS	1 Sell rating(s)	10 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pulse Biosciences has a beta of 1.63, indicating that its stock price is 63% more volatile than the broader market. Comparatively, Smith & Nephew SNATS has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Summary

Pulse Biosciences beats Smith & Nephew SNATS on 9 of the 15 factors compared between the two stocks.

How does Pulse Biosciences compare to Globus Medical?

Globus Medical (NYSE:GMED) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, institutional ownership, valuation, profitability and media sentiment.

Globus Medical currently has a consensus price target of $101.77, indicating a potential upside of 35.16%. Pulse Biosciences has a consensus price target of $45.25, indicating a potential downside of 8.79%. Given Globus Medical's stronger consensus rating and higher possible upside, equities research analysts clearly believe Globus Medical is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	3 Strong Buy rating(s)	2.88
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Globus Medical has higher revenue and earnings than Pulse Biosciences. Pulse Biosciences is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.44	$537.87M	$3.91	19.26
Pulse Biosciences	$350K	9,810.02	-$72.78M	-$1.18	N/A

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 74.0% of Pulse Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Globus Medical has a net margin of 17.02% compared to Pulse Biosciences' net margin of -6,755.78%. Globus Medical's return on equity of 14.57% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	17.02%	14.57%	12.62%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

In the previous week, Pulse Biosciences had 3 more articles in the media than Globus Medical. MarketBeat recorded 11 mentions for Pulse Biosciences and 8 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat Pulse Biosciences' score of 0.77 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.63, meaning that its share price is 63% more volatile than the broader market.

Summary

Globus Medical beats Pulse Biosciences on 13 of the 17 factors compared between the two stocks.

How does Pulse Biosciences compare to Glaukos?

Glaukos (NYSE:GKOS) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations, institutional ownership and media sentiment.

Pulse Biosciences has lower revenue, but higher earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than Pulse Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	18.96	-$187.69M	-$3.25	N/A
Pulse Biosciences	$350K	9,810.02	-$72.78M	-$1.18	N/A

Glaukos has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.63, meaning that its stock price is 63% more volatile than the broader market.

Glaukos presently has a consensus target price of $178.08, indicating a potential upside of 9.19%. Pulse Biosciences has a consensus target price of $45.25, indicating a potential downside of 8.79%. Given Glaukos' higher possible upside, research analysts clearly believe Glaukos is more favorable than Pulse Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.79
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Pulse Biosciences had 6 more articles in the media than Glaukos. MarketBeat recorded 11 mentions for Pulse Biosciences and 5 mentions for Glaukos. Glaukos' average media sentiment score of 1.14 beat Pulse Biosciences' score of 0.77 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pulse Biosciences	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Glaukos has a net margin of -30.68% compared to Pulse Biosciences' net margin of -6,755.78%. Glaukos' return on equity of -6.37% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

99.0% of Glaukos shares are held by institutional investors. Comparatively, 77.0% of Pulse Biosciences shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Pulse Biosciences beats Glaukos on 9 of the 17 factors compared between the two stocks.

Get Pulse Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PLSE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PLSE vs. The Competition

Export

Metric	Pulse Biosciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.82B	$5.55B	$7.22B	$14.93B
Dividend Yield	N/A	1.79%	2.57%	12.31%
P/E Ratio	-42.04	25.27	273.86	25.33
Price / Sales	9,810.02	68.63	643.61	87.33
Price / Cash	N/A	32.69	76.40	50.90
Price / Book	41.69	5.83	10.33	6.24
Net Income	-$72.78M	$151.55M	$3.49B	$358.55M
7 Day Performance	-8.86%	-0.58%	-0.84%	-1.20%
1 Month Performance	6.03%	-3.69%	-1.37%	-4.26%
1 Year Performance	204.92%	22.60%	21.13%	5.47%

Pulse Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PLSE Pulse Biosciences	1.6829 of 5 stars	$49.61 -10.1%	$45.25 -8.8%	+198.1%	$3.82B	$350K	N/A	116
BAX Baxter International	1.3722 of 5 stars	$24.87 -3.7%	$22.45 -9.7%	-1.5%	$13.35B	$11.24B	N/A	37,500	Positive News
PEN Penumbra	3.494 of 5 stars	$319.38 -0.9%	$367.07 +14.9%	+21.3%	$12.69B	$1.40B	78.47	4,700	Positive News
SNN Smith & Nephew SNATS	2.5469 of 5 stars	$27.84 -3.6%	$30.93 +11.1%	-25.6%	$12.12B	$6.30B	N/A	16,988	Gap Up High Trading Volume
GMED Globus Medical	4.4657 of 5 stars	$75.03 -4.2%	$101.77 +35.6%	+30.3%	$10.51B	$2.94B	19.19	6,000	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PLSE) was last updated on 9/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pulse Biosciences (PLSE) Competitors

PLSE vs. BAX, PEN, SNN, GMED, and GKOS

How does Pulse Biosciences compare to Baxter International?

Summary

How does Pulse Biosciences compare to Penumbra?

Summary

How does Pulse Biosciences compare to Smith & Nephew SNATS?

Summary

How does Pulse Biosciences compare to Globus Medical?

Summary

How does Pulse Biosciences compare to Glaukos?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pulse Biosciences (PLSE) Competitors

PLSE vs. BAX, PEN, SNN, GMED, and GKOS

How does Pulse Biosciences compare to Baxter International?

Which has more risk & volatility, PLSE or BAX?

Is PLSE or BAX more profitable?

Does the media prefer PLSE or BAX?

Which has stronger valuation & earnings, PLSE or BAX?

Do insiders and institutionals have more ownership in PLSE or BAX?

Do analysts prefer PLSE or BAX?

Summary

How does Pulse Biosciences compare to Penumbra?

Do analysts rate PLSE or PEN?

Which has more volatility & risk, PLSE or PEN?

Does the media prefer PLSE or PEN?

Which has better earnings and valuation, PLSE or PEN?

Do insiders & institutionals have more ownership in PLSE or PEN?

Is PLSE or PEN more profitable?

Summary

How does Pulse Biosciences compare to Smith & Nephew SNATS?

Is PLSE or SNN more profitable?

Do insiders & institutionals have more ownership in PLSE or SNN?

Does the media refer more to PLSE or SNN?

Which has preferable earnings and valuation, PLSE or SNN?

Do analysts prefer PLSE or SNN?

Which has more risk and volatility, PLSE or SNN?

Summary

How does Pulse Biosciences compare to Globus Medical?

Do analysts prefer GMED or PLSE?

Which has preferable valuation and earnings, GMED or PLSE?

Do institutionals and insiders have more ownership in GMED or PLSE?

Is GMED or PLSE more profitable?

Does the media prefer GMED or PLSE?

Which has more risk & volatility, GMED or PLSE?

Summary

How does Pulse Biosciences compare to Glaukos?

Which has stronger valuation and earnings, GKOS or PLSE?

Which has more risk and volatility, GKOS or PLSE?

Do analysts prefer GKOS or PLSE?

Does the media favor GKOS or PLSE?

Is GKOS or PLSE more profitable?

Do insiders & institutionals hold more shares of GKOS or PLSE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PLSE vs. The Competition

Pulse Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools